ClinicalTrials.gg
RecruitingNCT07455851Updated Nov 5, 2026

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1/2 interventional study of Linvoseltamab and REGN17372+Linvoseltamab in Relapsed Refractory Multiple Myeloma (RRMM), sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 5, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Planned enrollment
9th of 16
150 · median 168
Started
2026
with 6 others
Phase 1/2
5 of 16
4 open now
Primary completion
2033-09
later than 11 of 14 live
Registered
16th of 16
by date
Lead sponsor
10 of 16
Regeneron Pharmaceuticals

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 9th largest by planned enrollment, is one of 7 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 14 other live ones, and was the 16th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans.

The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone.

The study is looking at:

  • What side effects may happen from taking REGN17372 with linvoseltamab
  • How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma
  • What is the best dose of REGN17372 when given with linvoseltamab
  • How much study drug(s) are in the blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
  • If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)
03

Conditions studied

  • Relapsed Refractory Multiple Myeloma (RRMM)

Browse trials for

Keywords

  • B-cell maturation antigen (BCMA)
  • Anti-CD3 monoclonal antibodies (mAbs)
  • G-protein-coupled receptor class C group 5 member D (GPRC5D)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with RRMM who have exhausted (or are not a candidate for) all therapeutic options that are expected to provide meaningful clinical benefit and have received at least 3 as defined in the protocol
  2. performance status score ≤1
  3. Participants must have for response assessment as described in the protocol
  4. Adequate hematologic, cardiac, hepatic, and renal function, as described in the protocol

Key Exclusion Criteria:

  1. Participants with non-secretory MM, active plasma cell leukemia, known amyloidosis, Waldenström macroglobulinemia, or known POEMS syndrome as defined in the protocol
  2. Participants who have known MM brain lesions or CNS involvement
  3. Participants with a history of PML, a neurocognitive condition or CNS movement disorder, or a history of seizure within 12 months prior to entering screening
  4. Prior treatment with GPRC5D-directed immunotherapies (phase 1 and phase 2) and/or prior treatment with a BCMAxCD3 bispecific antibody (phase 2)

Note: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    REGN17372 + Linvoseltamab

    Phase 1 Phase 2

    Drug: REGN17372+Linvoseltamab

  • Active comparator
    Linvoseltamab monotherapy

    Phase 2

    Drug: Linvoseltamab

Interventions

  • Administered per protocol

    Also known as: Lynozyfic™, REGN5458

  • DrugREGN17372+Linvoseltamab

    Drug page: Linvoseltamab

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 35 days

  2. Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 5 years

  3. Severity of TEAEs associated with REGN17372 in combination with linvoseltamab

    Phase 1

    Time frame: Up to 5 years

  4. Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  5. VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  6. Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugs

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

  7. PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy

    Phase 2

    Time frame: Within 12 weeks of starting cycle 1

Secondary outcomes

  1. Concentrations of REGN17372 in serum

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  2. Concentrations of linvoseltamab in serum

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  3. Occurrence of Anti-Drug Antibodies (ADA) to REGN17372

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  4. Magnitude of ADA to REGN17372

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  5. Incidence of ADA to linvoseltamab

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  6. Magnitude of ADA to linvoseltamab

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  7. Objective Response Rate (ORR) as assessed by IMWG response criteria as determined by the investigator

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  8. Complete response (CR) as assessed by IMWG response criteria as determined by the investigator

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  9. VGPR as assessed by IMWG response criteria, as determined by the investigator

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  10. Duration of Response (DOR) as assessed by IMWG criteria as determined by the investigator

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  11. Progression Free Survival (PFS) as assessed by IMWG criteria as determined by the investigator

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  12. Minimal Residual Disease (MRD) negative status (at 10^-5) in participants in CR or better

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  13. Overall Survival (OS)

    Phase 1 and Phase 2

    Time frame: Up to 5 years

  14. ORR as assessed using the IMWG response criteria as determined by the investigator in patients receiving combination study drugs

    Phase 1

    Time frame: Within 12 weeks of starting cycle 1

  15. VGPR assessed using IMWG criteria as determined by the investigator in patients receiving combination study drugs

    Phase 1

    Time frame: Within 12 weeks of starting cycle 1

  16. Incidence of TEAEs

    Phase 2

    Time frame: Up to 5 years

  17. Severity of TEAEs

    Phase 2

    Time frame: Up to 5 years

  18. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Global Health Status / Quality of Life (GHS/QoL)

    Phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much"

    Time frame: Up to 5 years

  19. Change from baseline in EORTC QLQ-C30 Physical Functioning (PF)

    Phase 2

    Time frame: Up to 5 years

  20. Change from baseline in EORTC QLQ-C30 Role Functioning (RF)

    Phase 2

    Time frame: Up to 5 years

  21. Change from baseline in EORTC QLQ-C30 pain

    Phase 2

    Time frame: Up to 5 years

  22. Change from baseline in EORTC QLQ-C30 fatigue

    Phase 2

    Time frame: Up to 5 years

  23. Time to definitive deterioration in EORTC QLQ-C30 GHS/QoL

    Phase 2

    Time frame: Up to 5 years

  24. Time to definitive deterioration in EORTC QLQ-C30 PF

    Phase 2

    Time frame: Up to 5 years

  25. Time to definitive deterioration in EORTC QLQ-C30 RF

    Phase 2

    Time frame: Up to 5 years

  26. Time to definitive deterioration in EORTC QLQ-C30 pain

    Phase 2

    Time frame: Up to 5 years

  27. Time to definitive deterioration in EORTC QLQ-C30 fatigue

    Phase 2

    Time frame: Up to 5 years

  28. Time to first improvement in EORTC QLQ-C30 GHS/QoL

    Phase2

    Time frame: Up to 5 years

  29. Time to first improvement in EORTC QLQ-C30 PF

    Phase 2

    Time frame: Up to 5 years

  30. Time to first improvement in EORTC QLQ-C30 RF

    Phase 2

    Time frame: Up to 5 years

  31. Time to first improvement in EORTC QLQ-C30 pain

    Phase 2

    Time frame: Up to 5 years

  32. Time to first improvement in EORTC QLQ-C30 fatigue

    Phase 2

    Time frame: Up to 5 years

  33. Change from baseline in EORTC QLQ-Multiple Myeloma Module (MY20) Disease Symptoms (DS)

    Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems

    Time frame: Up to 5 years

  34. Time to definitive deterioration in EORTC QLQ-MY20 DS

    Phase 2

    Time frame: Up to 5 years

  35. Time to first improvement in EORTC QLQ-MY20 DS

    Phase 2

    Time frame: Up to 5 years

  36. Change from baseline in EORTC QLQ-MY20 Treatment Side Effects (TSE)

    Phase 2

    Time frame: Up to 5 years

  37. Time to definitive deterioration in EORTC QLQ-MY20 TSE

    Phase 2

    Time frame: Up to 5 years

  38. Time to first improvement in EORTC QLQ-MY20 TSE

    Phase 2

    Time frame: Up to 5 years

  39. Change from baseline in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS)

    Phase 2 The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems

    Time frame: Up to 5 years

  40. Time to definitive deterioration in EQ-5D-5L VAS

    Phase 2

    Time frame: Up to 5 years

  41. Time to first improvement in EQ-5D-5L VAS

    Phase 2

    Time frame: Up to 5 years

  42. Patient-reported overall impact of treatment toxicity measured by Functional Assessment of Cancer Therapy (FACIT) Item GP5

    Phase 2 The FACIT Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much)

    Time frame: Up to 5 years

  43. Patient-reported tolerability as measured by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Phase 2 The PRO-CTAE questionnaire assesses side effects and symptoms in cancer clinical trials using a PRO-CTCAE score. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic AEs drawn from the CTCAE

    Time frame: Up to 5 years

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2033, 90 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 90 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Sep 30, 2033
CompletionEst.
Sep 30, 2033
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Australia, 1 Greece)
  • South Western Sydney Local Health District - Liverpool Hosptial · Liverpool, Australia
  • 1st Health Region of Athens, Alexandra General Hospital of Athens · Athens, Greece
Show 1 removed
  • Alexandra Hospital · Athens, Greece
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Australia, 1 Greece)
    • South Western Sydney Local Health District - Liverpool Hosptial · Liverpool, Australia
    • 1st Health Region of Athens, Alexandra General Hospital of Athens · Athens, Greece
    Show 1 removed
    • Alexandra Hospital · Athens, Greece
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07455851
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 26, 2026
Primary completion
Sep 30, 2033 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Nov 5, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion